Topic
Ammonium tetrathiomolybdate
About: Ammonium tetrathiomolybdate is a research topic. Over the lifetime, 187 publications have been published within this topic receiving 4249 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: In this paper, an ammonium tetrathiomolybdate (ATTM) is treated with cetyltrimethylammonium chloride (CTAC) using several ATTM/CTAC ratios.
15 citations
TL;DR: By Fourier transform high-resolution NMR spectroscopy, the 95Mo resonance lines of the tetrathiomolybdate species Mo32S42− and Mo 32S334S2− have been resolved in aqueous solutions of potassium-and ammonium tetrathymolebdate.
Abstract: By Fourier transform high resolution NMR spectroscopy the95Mo resonance lines of the tetrathiomolybdate species Mo32S42− and Mo32S334S2− have been resolved in aqueous solutions of potassium- and ammonium tetrathiomolybdate. An isotope effect on the Larmor frequency of (0.09±0.01) ppm to lower frequency was found for the substitution of a32S atom by a34S atom in the MoS42− ion.
14 citations
TL;DR: There was a trend towards reduced striatal degeneration, suggesting a neuroprotective effect of ammonium tetrathiomolybdate in this model of Huntington disease, and its known tolerability in humans with neurodegeneration could be considered as a candidate for clinical trials in Huntington disease.
14 citations
TL;DR: An improved ex situ presulfidation method for the preparation of the CoMoS/γ-Al2O3 catalyst was developed with ammonium sulfide as the sulfiding agent, and the prepared catalysts were evaluated in selective hydrodesulfurization of fluid catalytic cracking (FCC) gasoline.
Abstract: An improved ex situ presulfidation method for the preparation of the CoMoS/γ-Al2O3 catalyst was developed with ammonium sulfide as the sulfiding agent, and the prepared catalysts were evaluated in selective hydrodesulfurization (HDS) of fluid catalytic cracking (FCC) gasoline. The selectivity of the ex situ presulfided catalysts was more than 4 times of that of the in situ presulfided catalysts. The characterization by XRD, HRTEM, XPS, TPR, and FT-IR indicated that ammonium sulfide effectively reacted with the supported Mo oxide to form ammonium tetrathiomolybdate as intermediate, thus realizing the more complete sulfidation of Mo oxide. However, the supported Co oxide could not be sulfided by ammonium sulfide, and the delayed sulfidation would not hinder the easy growth of MoS2 particles, subsequently lead to the significantly longer slab lengths of MoS2 particles than that of the in situ presulfided catalyst, which effectively decreased the number of active sites for olefins, thus inducing much higher H...
14 citations
TL;DR: The anti-cancer efficacy of low doses of TTM and DSF are compared, asking whether they can be synergistic or antagonistic, and the relevance of their unequal ROS inducing abilities, and their different behavior as ionophores is also addressed.
Abstract: Background Copper (Cu) is a transition metal active in Fenton redox cycling from reduced Cu+ and H2O2, to oxidized Cu2+ and the hydroxyl radical (·OH) highly reactive oxygen species (ROS). At homeostatic Cu levels, ROS promote cell proliferation, migration, angiogenesis, and wound repair. To limit ROS toxicity, cells use Cu-dependent chaperone proteins, Cu-binding ceruloplasmin, and Cu-modulated enzymes like superoxide dismutases (SOD) like SOD1 and SOD3 to scavenge excess superoxide anions which favour Cu+ reduction, and mitochondrial cytochrome c oxidase, important in aerobic energy production. Because Cu helps drive tumor cell proliferation by promoting growth factor-independent receptor tyrosine kinase signaling, and Cu-dependent MEK1 involved in oncogenic BRAF-V600E signaling, further augmenting bioavailable Cu may promote ROS overproduction, cancer progression and eventually tumor cell death. For these reasons, the following clinically approved copper chelators are being repurposed as anti-cancer agents: a) ammonium tetrathiomolybdate (TTM) used to treat Wilson's disease (copper overload) and Menkes disease (copper deficiency); b) Disulfiram (DSF), used against alcoholism, since it inhibits Aldehyde Dehydrogenase (ALDH1) enzyme, important in ethanol detoxification, and a key target against cancer stem cells. Moreover, TTM and DSF are also relevant in cancer clinical trials, because they increase the uptake of both Cu and Platinum (Pt)-containing anti-cancer drugs, since Pt and Cu share the same CTR1 copper transporter. Purpose The majority of reports on Cu chelators dealt separately with either TTM, DSF or others. Here, we compare in parallel, the anti-cancer efficacy of low doses of TTM and DSF, asking whether they can be synergistic or antagonistic. The relevance of their unequal ROS inducing abilities and their different behavior as ionophores is also addressed. Significance The potential of Cu chelators as repurposed anti-cancer drugs, should be greater in patients with higher endogenous Cu levels. Since platinum and Cu share uptake receptors, the synergism by drugs containing these metals should not be under-estimated. The potential of disulfiram or its metabolically active Cu-containing form, to inhibit ALDH1-positive tumor cells is therapeutically very important.
14 citations